Sam­sung Bi­o­log­ics, TG Ther­a­peu­tics ink deal to mass pro­duce MS hope­ful ubli­tux­imab

As Sam­sung Bi­o­log­ics looks to dra­mat­i­cal­ly scale its pro­duc­tion with a $2 bil­lion “su­per plant” in In­cheon, South Ko­rea, it’s sign­ing on part­ners to fill …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER